Skip to content

Main Navigation

Vor Bio
  • News & Media
  • Publications
  • Medical Professionals
  • Contact
  • Blog
  • Search
  • About Us
    • Overview
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • Overview
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Overview
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Overview
    • What is AML?
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Join Us
    • Overview
    • Values & Culture
    • Benefits
    • Open Positions
    • Co-Op Program
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts

Publication Type: Poster Presentation

G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models

ASH – 2021 – Poster Presentation 1716 […]

Read More… from G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models

Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety

ASH – 2021 – Poster Presentation 2939 […]

Read More… from Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety

Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment

ASH – 2021 – Poster Presentation 3818 […]

Read More… from Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment

An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs

SITC – 2021 – Poster Presentation 115 […]

Read More… from An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs

Construction and Evaluation of Interleukin 3 (IL3)-Zetakine–Redirected Cytolytic T Cells for Treatment of CD123-Expressing Acute Myeloid Leukemia

SITC – 2021 – Poster Presentation 871 […]

Read More… from Construction and Evaluation of Interleukin 3 (IL3)-Zetakine–Redirected Cytolytic T Cells for Treatment of CD123-Expressing Acute Myeloid Leukemia

In Depth Assessment of Off-target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

ESGCT – 2021 – Poster Presentation P112 […]

Read More… from In Depth Assessment of Off-target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

ASGCT – 2021 – Poster Presentation 858 […]

Read More… from Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

Posts navigation

  • «
  • 1
  • …
  • 3
  • 4
  • 5

Share This Post

Recent Vor Voices

  • A Legacy of Hope and Discovery April 10, 2025
  • Earning vs Deserving December 22, 2024
  • Satisfaction in Excellence November 24, 2024
  • Comfort is the Enemy? November 4, 2024
  • Remembering a Life and Embracing Hope: My Family’s Journey with AML and Our Fight for a Cure September 23, 2024
  • Understanding not just the jigsaw piece, but the entire puzzle September 10, 2024
  • Affinity vs Ability: Finding Work That Fits Your Personality August 23, 2024
  • Finding Joy in Work August 19, 2024
  • Fellowship in Action: Our First In-House Manufacturing Run June 26, 2024
Logo Vor Biopharma White

Follow us on social media:

Twitter LinkedIn Instagram

Boston Business Journal Badge 2023 2024
Read more about
working at Vor Bio

  • About Us
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • What is AML?
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Our Investigational Programs
    • Clinical Trials
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts
  • News & Media
  • Publications
  • Join Us
  • Blog

© 2025 Vor Bio

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.